专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明专利

NO20005887L 未知
公开(公告)号：NO20005887L
公开(公告)日：2001-01-19
申请号：NO20005887
申请日：2000-11-21
申请人： AVANIR PHARMACEUTICALS
发明人： SIRCAR JAGADISH , RICHARDS MARK L , CAMPBELL MICHAEL G , MAJOR MICHAEL W
IPC分类号： C07D235/14 , A61K31/00 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/337 , A61K31/357 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/4035 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4184 , A61K31/42 , A61K31/423 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/445 , A61K31/451 , A61K31/454 , A61K31/4545 , A61K31/53 , A61K45/06 , A61P11/06 , A61P37/08 , A61P43/00 , C07D205/04 , C07D209/16 , C07D209/48 , C07D211/46 , C07D211/52 , C07D235/18 , C07D251/70 , C07D261/12 , C07D319/18 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/04 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04
摘要： The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

32. 发明专利

NO20005889D0 未知
公开(公告)号：NO20005889D0
公开(公告)日：2000-11-21
申请号：NO20005889
申请日：2000-11-21
申请人： AVANIR PHARMACEUTICALS
发明人： SIRCAR JAGADISH , RICHARDS MARK L , CAMPBELL MICHAEL G , MAJOR MICHAEL W
IPC分类号： C07D235/14 , A61K31/00 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/337 , A61K31/357 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/4035 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4184 , A61K31/42 , A61K31/423 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/445 , A61K31/451 , A61K31/454 , A61K31/4545 , A61K31/53 , A61K45/06 , A61P11/06 , A61P37/08 , A61P43/00 , C07D205/04 , C07D209/16 , C07D209/48 , C07D211/46 , C07D211/52 , C07D235/18 , C07D251/70 , C07D261/12 , C07D319/18 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/04 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , A61K
摘要： The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

33. 发明专利

CA2332999A1 COMPOUNDS HAVING IGE AFFECTING PROPERTIES 未知
公开(公告)号：CA2332999A1
公开(公告)日：1999-12-02
申请号：CA2332999
申请日：1999-05-21
申请人： AVANIR PHARMACEUTICALS
发明人： RICHARDS MARK L , SIRCAR JAGADISH , CAMPBELL MICHAEL G , MAJOR MICHAEL W
IPC分类号： C07D235/14 , A61K31/00 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/337 , A61K31/357 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/4035 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4184 , A61K31/42 , A61K31/423 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/445 , A61K31/451 , A61K31/454 , A61K31/4545 , A61K31/53 , A61K45/06 , A61P11/06 , A61P37/08 , A61P43/00 , C07D205/04 , C07D209/16 , C07D209/48 , C07D211/46 , C07D211/52 , C07D235/18 , C07D251/70 , C07D261/12 , C07D319/18 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/04 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , A61K31/335 , A61K31/135 , A61K31/165 , A61K31/395 , A61K31/40 , A61K31/535
摘要： The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

34. 发明专利

CA2332989A1 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IGE 未知
公开(公告)号：CA2332989A1
公开(公告)日：1999-12-02
申请号：CA2332989
申请日：1999-05-21
申请人： AVANIR PHARMACEUTICALS
发明人： CAMPBELL MICHAEL G , MAJOR MICHAEL W , RICHARDS MARK L , SIRCAR JAGADISH
IPC分类号： C07D235/14 , A61K31/00 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/337 , A61K31/357 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/4035 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4184 , A61K31/42 , A61K31/423 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/445 , A61K31/451 , A61K31/454 , A61K31/4545 , A61K31/53 , A61K45/06 , A61P11/06 , A61P37/08 , A61P43/00 , C07D205/04 , C07D209/16 , C07D209/48 , C07D211/46 , C07D211/52 , C07D235/18 , C07D251/70 , C07D261/12 , C07D319/18 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/04 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04
摘要： This invention relates to a family of diacyl benzimidazole analogs, which ar e inhibitors of the IgE response to allergens. These compounds are useful in t he treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

35. 发明专利

AT461920T 未知
公开(公告)号：AT461920T
公开(公告)日：2010-04-15
申请号：AT02731971
申请日：2002-05-24
申请人： AVANIR PHARMACEUTICALS
发明人： GAETA FEDERICO , BAIRD ANDREW , ANCHIN JERRY , YING WENBIN , FLORKIEWICZ ROBERT , SIRCAR JAGADISH , KUMAR SUNIL K C
IPC分类号： C07D215/42 , C12Q1/02 , A61K31/47 , A61K31/4706 , A61K31/496 , A61K31/497 , A61K45/00 , A61P1/04 , A61P3/10 , A61P5/08 , A61P5/46 , A61P9/00 , A61P11/00 , A61P11/06 , A61P13/12 , A61P19/02 , A61P25/28 , A61P29/00 , A61P35/00 , A61P37/06 , A61P43/00 , C07D215/46 , C07D215/54 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12
摘要： Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

36. 发明专利

MX2008011904A INHIBIDORES ALFA DE FACTOR DE NECROSIS DE TUMOR Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES HUMANAS. 未知
公开(公告)号：MX2008011904A
公开(公告)日：2009-02-10
申请号：MX2008011904
申请日：2007-03-20
申请人： AVANIR PHARMACEUTICALS
发明人： SIRCAR JAGADISH , KUMAR SUNIL K C , DAVIS TIMOTHY JAMES , YING WENBIN , NUSSBAUMER PETER , AICHHOLZ REINER , BILLICH ANDREAS
IPC分类号： C07D215/46 , A61K31/4709 , A61P31/00 , A61P35/00 , C07D401/06 , C07D409/12 , C07D487/08 , C07D491/04 , C07D495/04
摘要： Se proporcionan inhibidores de factor alfa de necrosis de tumor que tienen utilidad en el tratamiento de una variedad de desórdenes, incluyendo el tratamiento de condiciones patológicas asociadas con factor alfa de necrosis de tumor. Los inhibidores de factor alfa de necrosis de tumor tienen las siguientes estructuras: (I) incluyen estereoisómeros, sus sales y solvatos farmacéuticamente aceptables, en donde los sustituyentes son como se define aquí. También se proporcionan composiciones que contienen un inhibidor de factor alfa de necrosis de tumor, en combinación con un portador farmacéuticamente aceptable, así como métodos para uso de las mismas.

37. 发明专利

AU2002303906B2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same 未知
公开(公告)号：AU2002303906B2
公开(公告)日：2007-06-28
申请号：AU2002303906
申请日：2002-05-24
申请人： AVANIR PHARMACEUTICALS
发明人： FLORKIEWICZ ROBERT , BAIRD ANDREW , SUNIL KUMAR K C , SIRCAR JAGADISH , GAETA FEDERICO C A , ANCHIN JERRY , YING WENBIN
IPC分类号： C12Q1/02 , A61K31/47 , A61K31/496 , A61K31/497 , A61K45/00 , A61P1/04 , A61P3/10 , A61P5/08 , A61P5/46 , A61P9/00 , A61P11/00 , A61P11/06 , A61P13/12 , A61P19/02 , A61P25/28 , A61P29/00 , A61P35/00 , A61P37/06 , A61P43/00 , C07D215/42 , C07D215/46 , C07D215/54 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12
摘要： Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

38. 发明专利

DE69924607T2 未知
公开(公告)号：DE69924607T2
公开(公告)日：2006-02-02
申请号：DE69924607
申请日：1999-05-21
申请人： AVANIR PHARMACEUTICALS SAN DIE
发明人： SIRCAR JAGADISH , RICHARDS L , CAMPBELL G , MAJOR W
IPC分类号： C07D235/14 , A61K31/00 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/337 , A61K31/357 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/4035 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4184 , A61K31/42 , A61K31/423 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/445 , A61K31/451 , A61K31/454 , A61K31/4545 , A61K31/53 , A61K45/06 , A61P11/06 , A61P37/08 , A61P43/00 , C07D205/04 , C07D209/16 , C07D209/48 , C07D211/46 , C07D211/52 , C07D235/18 , C07D251/70 , C07D261/12 , C07D319/18 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/04 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04
摘要： The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

39. 发明专利

AR045471A1 DERIVADOS DE NAFTIRIDINA SUSTITUIDOS COMO INHIBIDORES DEL FACTOR INHIBIDOR DE LA MIGRACION DE MACROFAGOS Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES EN EL HOMBRE 未知
公开(公告)号：AR045471A1
公开(公告)日：2005-10-26
申请号：ARP040102991
申请日：2004-08-20
申请人： AVANIR PHARMACEUTICALS
发明人： SIRCAR JAGADISH , KUMAR K C SUNIL , YING WENBIN
IPC分类号： A61P29/02 , A61P35/00 , A61P37/06 , C07D471/04 , A61K31/4375 , A61P37/02 , A61P29/00 , C07D221/00
摘要： Se proveen inhibidores del factor inhibidor de la migración de macrófagos (MIF) con una estructura principal de naftiridina que son de utilidad en el tratamiento de una variedad de trastornos, incluyendo el tratamiento de afecciones patológicas asociadas con la actividad del MIF. Los inhibidores del MIF tienen las estructuras de las fórmulas (1), que incluyen estereoisómeros, prodrogas y sales aceptables para uso farmacéutico de los mismos. También se proveen composiciones que contienen un inhibidor de MIF en combinación con un vehículo aceptable para uso farmacéutico, así como métodos para utilizarlos. Reivindicación 1: Un compuesto donde, R se selecciona entre el grupo que consiste en hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilalquilo, acilalquilo sustituido, heterociclo, heterociclo sustituido, -(CH2)mC(=O)Ar, y -(CH2)mNR4R5; R1 se selecciona entre el grupo que consiste en -CN, -NO, -NO2, -C(=O)R3, -C(=O)OH, -NHC(=O)R3, -C(=O)OR3, -C(=O)NR4R5, -NR3C(=O)R3, -SO2NR4R5, -NR3SO2R3, -NHSO2R3, -S(O)mR3, -(CH2)mNR4R5, y -(CH2)mC(=O)Ar; R2 se selecciona entre el grupo que consiste en - CH2R3, -NR4R5, -OR3, y -R3; R3 se selecciona independientemente entre el grupo que consiste en alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilalquilo, acilalquilo sustituido, heterociclo, heterociclo sustituido; R4 y R5 se seleccionan independientemente entre el grupo que consiste en hidrógeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, arilalquilo, arilalquilo sustituido, acilalquilo, acilalquilo sustituido, heterociclo, y heterociclo sustituido, o R4 y R5 tomados juntos comprenden heterociclo o heterociclo sustituido; X se selecciona entre el grupo que consiste en hidrógeno, halógeno, -F, -Cl, -CN, -NO, -NO2, -OCF3, -CF3, -NHSO2R3, -C(=O)R3, -C(=O)OR3, -C(=O)NR4R5, -NR3C(=O)R3, -NR3SO2R3, -S(O)mR3, -R3, -OR3, -SR3, -C(=O)OH, -NHC(=O)R3, y -NR4R5; Y se selecciona entre el grupo que consiste en hidrógeno, halógeno, -F, -Cl, -CN, -NO, -NO2, -OCF3, -CF3, -NHSO2R3, -C(=O)R3, -C(=O)OR3, -C(=O)NR4R5, -NR3C(=O)R3, -NR3SO2R3, -S(O)mR3, -R3, -OR3, -SR3, -C(=O)OH, -NHC(=O)R3, y -NR4R5; Z se selecciona entre el grupo que consiste en hidrógeno, halógeno, -F, -Cl, -CN, -NO, -NO2, -OCF3, -CF3, -NHSO2R3, -C(=O)R3, -C(=O)OR3, -C(=O)NR4R5, -NR3C(=O)R3, -NR3SO2R3, -S(O)mR3, -R3, -OR3, -SR3, -C(=O)OH, -NHC(=O)R3, y -NR4R5; Ar se selecciona entre el grupo que consiste en arilo y arilo sustituido; m es independientemente 0, 1, 2, 3 ó 4; y n es 0, 1 ó 2.

40. 发明专利

ES2241285T3 DERIVADOS BENCIMIDAZOL COMO MODULADORES DE IGE. 未知
公开(公告)号：ES2241285T3
公开(公告)日：2005-10-16
申请号：ES99924442
申请日：1999-05-21
申请人： AVANIR PHARMACEUTICALS
发明人： SIRCAR JAGADISH , RICHARDS MARK L , CAMPBELL MICHAEL G , MAJOR MICHAEL W
IPC分类号： C07D235/14 , A61K31/00 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/337 , A61K31/357 , A61K31/382 , A61K31/397 , A61K31/403 , A61K31/4035 , A61K31/404 , A61K31/4045 , A61K31/415 , A61K31/4184 , A61K31/42 , A61K31/423 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/445 , A61K31/451 , A61K31/454 , A61K31/4545 , A61K31/53 , A61K45/06 , A61P11/06 , A61P37/08 , A61P43/00 , C07D205/04 , C07D209/16 , C07D209/48 , C07D211/46 , C07D211/52 , C07D235/18 , C07D251/70 , C07D261/12 , C07D319/18 , C07D401/12 , C07D401/14 , C07D403/14 , C07D405/04 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04
摘要： Composición farmacéutica que comprende los compuestos siguientes: donde X e Y se seleccionan, independientemente entre si, de entre el grupo compuesto por H, alquilo, alcoxi, arilo, arilo sustituido, hidroxilo, halógeno, amino, alquilamino, nitro, ciano, CF3, OCF3, CONH2, CONHR y NHCOR1; R se selecciona de entre el grupo compuesto por H, CH3, C2H5, C3H7, C4H9, CH2Ph, y CH2C6H4-F(p-); y R1 y R2 se seleccionan, independientemente entre si, de entre el grupo compuesto por H, arilo, arilo sustituido, cicloarilo, cicloarilo sustituido, cicloarilo de anillos múltiples, bencilo, bencilo sustituido, alquilo, cicloalquilo, cicloalquilo sustituido, cicloalquilo de anillos múltiples, anillos condensados alifáticos, ciclopropilo, ciclopropilo sustituido, ciclobutilo, ciclobutilo sustituido, ciclopentilo, ciclopentilo sustituido, ciclohexilo, ciclohexilo sustituido, cicloheptilo, cicloheptilo sustituido, bicicloheptilo, biciclooctilo, biciclononilo, bicicloalquilo sustituido, adamantilo, y adamantilo sustituido, donde al menos uno de R1 y R2 es un grupo aromático y en la cual R1 y R2 no son ambos grupos fenilo.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式